GY036 for stage 3/4 gynecologic cancers with pathogenic BRCA 1/2 mutation or HR deficiency
Who Can Participate in the Study?
Age Group
Adults
Study Details
Full Title
NRG-GY036, A Phase III Trial of One vs. Two Years of Maintenance Olaparib, with or without Bevacizumab, in Patients with BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy (NCT#06580314)
Principal Investigator
Professor of Obstetrics and Gynecology
Protocol Number
IRB:
PRO00117512
NCT:
NCT06580314
Phase
Phase
III
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
OPEN TO ACCRUAL